Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

Ignace Vergote; Els Van Nieuwenhuysen; Stefanie De Waele; Christof Vulsteke; Caroline Lamot; Heidi Van den Bulck; Nele Claes; Marie-Pascale Graas; Guy Debrock; Isabelle Spoormans; Peter Vuylsteke; Brigitte Honhon; Didier Verhoeven; Daan De Maeseneer; Luc Dirix; Jeroen Mebis; Philippe Vroman; Hannelore Denys; Corina Martinez Mena; Gino Pelgrims; Mona Van Steenberghe; Toon van Gorp; Christine Gennigens

doi:10.1136/ijgc-2021-003190

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

PDF +
Supplementary
Material

Original research

Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group

Free

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password